About Event

Welcome To the Fusion Protein Engineering & Developability Summit 2023

The inaugural Fusion Proteins Engineering & Developability Summit explored recent advances in novel fusion proteins that have unlocked enhanced therapeutic efficacy, focused on the cutting edge of fusion protein application across Cytokine-, Ligand-, Enzyme- & Bispecific- Fusion Proteins. There were 3 hands-on workshops and 2 days of packed data-driven case studies from drug developers such as Roche, Merck & Co., Inc., Asher Bio, and AbbVie.

There was the opportunity to discover the latest and greatest in novel fusion proteins pushing the boundaries of safe targeted therapy with 60+ protein engineers and therapeutic developers to return to the office with practical insights to accelerate your novel fusion protein pipeline to market.

What went On?

Screenshot 2023-03-16 161713
  • Cutting-Edge Insights: Gain exclusive access to the latest breakthroughs in fusion protein engineering, encompassing the most recent research and emerging trends in this dynamic field.
Screenshot 2023-03-16 161713
  • Practical Learning: Immerse yourself in hands-on workshops led by industry experts, designed to enhance your skills and knowledge in must-know areas.
Screenshot 2023-03-16 161713
  • Real-World Case Studies: Immerse yourself in over 17+ data-driven case studies presented by renowned drug developers, offering profound insights and best practices.
Screenshot 2023-03-16 161713
  • Engaging Discussions: Engage in lively panel discussions and roundtable sessions, fostering debates and knowledge exchange on hot topics such as novel linker selection and the identification of PK/PD rules.
Screenshot 2023-03-16 161713
  • Networking Opportunities: Forge valuable connections with 60+ protein engineers, therapeutic developers, and influential industry leaders during 7+ hours of dedicated networking, including the renowned speed networking session.
Screenshot 2023-03-16 161713
  • Complimentary Drinks Reception: Continue the conversation in a more informal setting and take advantage of networking with you peers.

Companies Who Attended

12th HP Partners (end of page) (2)

Our 2023 Snapshot

34751 - Logos


“I’m looking forward to new ideas regarding protein engineering and design, evolution of chosen modalities and impact of those choices on developability.”

 Principal Scientist Molecular Discovery - Merck & Co., Inc.


“This summit offers great value to supporting the field by bringing together experts in complex fusion protein design, engineering, expression, preclinical and clinical development.”

Chief Scientific Officer - FuseBio 


“Very valuable”

Head of Cell, Gene, and Protein Engineering, Biotherapeutics – AbbVie

Resize - Speaker Images (9)